GSK gets US FDA approval for expanded use of RSV vaccine [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
respiratory syncytial virus vaccine, Arexvy, to ?include adults aged 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. * The vaccine ?is already approved ?in the U.S. for preventingRSV-related disease in adults aged 60 and above, ?and in at-riskadults aged 50 to 59. * RSV is a common respiratory virus that causes ?seasonalinfections such ?as the flu ?and is a ?leading cause of pneumoniaand death in infants and older adults. * In the U.S., an estimated 21 million adults under 50 haveat least one risk factor for severe RSV infection, the ?companysaid. * GSK's vaccine, Arexvy, ?would be competing for market ?sharein the ?18-49 age group with Moderna's mRESVIA ?and Pfizer'sAbrysvo. * In December, ?a panel ?of the European Medicines Agency hadalso backed the use of Arexvy for all adults ?above the ?age of18, paving the way for broader ?use. (Reporting by Siddhi Mahatole in Bengaluru; ?Editing by Devika Syamnath)
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation [Seeking Alpha]Seeking Alpha
- PENBRAYA (Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Ngenla (somatrogon: Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/12/26 - Form ARS
- 3/12/26 - Form DEFA14A
- 3/12/26 - Form DEF
- PFE's page on the SEC website